Atricure (ATRC) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Atricure (ATRC) do?
Atricure Inc (ATRC) is a U.S.-listed company in Healthcare (Medical Instruments & Supplies). What it does: Produces medical equipment to treat cardiac arrhythmias and freeze nerves during surgery. Sells these specialized instruments directly to cardiac surgeons performing hospital procedures. Manufactures surgical devices designed to treat atrial fibrillation and manage post-operative surgical pain through. It is worth $2.76B on the market and sold $590.02M over the last year.
- Market cap
- $2.76B
- P/E ratio
- 178.2×
- Annual sales
- $590.02M
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Brief updated
- Nov 14, 2026
Brands and businesses behind ATRC
- AtriClip: Left atrial appendage clip system sold to hospitals for open and minimally invasive surgical placement.
- cryoSPHERE: Cryoablation probe sold to hospitals for temporarily blocking post-operative pain through targeted nerve freezing.
- Isolator: Radiofrequency ablation clamp line sold to cardiac surgeons to create transmural lesions during heart surgery.
- EnCompass: Radiofrequency clamp sold to surgeons to ablate cardiac tissue during routine open-heart procedures.
ATRC’s flags, in plain English
Each flag is a number from Atricure’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Stupid Cash
Can pay this year's bills 4.3 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 76.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earnings Jumping
Profits up 202.6% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.
Priced for Perfection
Priced at 178.2 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about ATRC
How big is Atricure?
Atricure’s market cap is $2.76B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $590.02M: what customers paid the company over the last year, before any costs.
What is ATRC’s P/E ratio?
ATRC’s P/E ratio is 178.2×. Investors pay about 178.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ATRC?
Catheter-based pulsed-field ablation technologies compete directly with the company's minimally invasive cardiac ablation devices for patient volume. That is one risk on Atricure’s card. Its first risk flag is Priced for Perfection, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Atricure’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ATRC’s filings on SEC.gov. The Margin Monkey is research, not advice.
